


RXPA 380

Cat. No.:	HY-18205
CAS No.:	564479-79-4
Molecular Formula:	C ₃₃ H ₃₆ N ₃ O ₇ P
Molecular Weight:	617.63
Target:	Angiotensin-converting Enzyme (ACE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a K _i of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC ₅₀ of 2.5 nM ^[1] .	
IC₅₀ & Target	K _i : 3 nM (C-terminal ACE), 10 μM (N-terminal ACE) ^[1] IC ₅₀ : 2.5 nM (C-domain mutants of human recombinant ACE), 10 μM (N-domain mutants of human recombinant ACE) ^[1]	
In Vitro	RXPA 380 shows K _{i(app)} values of 12 nM and 12 μM for the C- and N-domain of mouse somatic ACE ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	RXPA 380 (0.9-30 mg/kg; i.v.; once) inhibits ACE activity in mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male C57BL6/J mice ^[1]
	Dosage:	0.9, 3, 10, and 30 mg/kg
	Administration:	Intravenous infuse for 30 minutes
	Result:	Induced a dose-dependent decrease of the Ang II/Ang I ratio. Blocked the cleavage of exogenously administered bradykinin.

REFERENCES

[1]. Georgiadis D, et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. *Circ Res.* 2003 Jul 25;93(2):148-54.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA